

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 226 418 B1**

**B11**

(12)

## EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 27.05.92 (51) Int. Cl.<sup>5</sup>: **A61K 47/00, A61K 37/02, A61K 35/74**
- (21) Application number: 86309515.4
- (22) Date of filing: 05.12.86

The file contains technical information submitted after the application was filed and not included in this specification

- (54) **Anti-human ovarian cancer immunotoxins and methods of use thereof.**

- (30) Priority: 06.12.85 US 806256

- (43) Date of publication of application:  
24.06.87 Bulletin 87/26

- (45) Publication of the grant of the patent:  
27.05.92 Bulletin 92/22

- (84) Designated Contracting States:  
AT BE CH DE FR GB IT LI NL SE

- (56) References cited:  
EP-A- 0 074 279  
EP-A- 0 121 388  
WO-A-83/00810

Chemical Abstracts, vol. 103, no. 22, 2. December 1985, column 1, abstract no. 190120e, Columbus, Ohio, US; M.A.LORINCZ et al.: "Monoclonal antibody recognition of multiple forms of strogen receptor tagged with 125 methoxy-iodovinyl estradiol in ovarian carcinomas"

- (73) Proprietor: **CETUS CORPORATION**  
1400 Fifty-Third Street  
Emeryville California 94608(US)

- (72) Inventor: Bjorn, Michael Jon  
109 Olive Court  
Hercules California 94547(US)  
Inventor: Frankel, Arthur Edward  
223 Huntington Drive  
Chapel North Carolina 27514(US)  
Inventor: Laird, Walter Joseph  
2660 Lassen Way  
Pinole California 94564(US)  
Inventor: Ring, David Barratt  
1248 Truman Street  
Redwood City California 94061(US)  
Inventor: Winkelhake, Jeffrey Lee  
c/o Cetus Corp. 1400 Fifty-Third Street  
Emeryville, California 94608(US)

- (74) Representative: Bizley, Richard Edward et al  
HEPWORTH LAWRENCE BRYER & BIZLEY  
2nd Floor Gate House South West Gate  
Harlow, Essex CM20 1JN(GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

## Description

This invention is in the fields of immunology and cancer diagnosis and therapy. More particularly it employs murine monoclonal antibodies active against human ovarian cancer, and concerns immunochem-  
icals made from fragments of those antibodies.

Among gynecological malignancies occurring in American women, ovarian cancer most frequently causes death. The malignancy remains confined to the peritoneal cavity during practically its entire clinical course. Characteristically the tumor disseminates throughout the peritoneal cavity producing acites and tumor foci on multiple peritoneal surfaces. The disease cannot be effectively cured surgically and chemotherapy is increasingly the primary treatment. Because ovarian tumors generally remain in the peritoneal cavity, chemotherapeutic agents may be administered systemically by intravenous injection or by direct infusion into the peritoneal cavity thus by-passing the circulatory system as the route for initially exposing the tumor to the chemotherapeutic agent.

The use of monoclonal antibodies against antigens associated with cancerous ovarian tissues has been reported to only a limited extent. An antibody to human transferrin receptor linked to *Pseudomonas* exotoxin has been reported to have cytotoxic activity in certain human ovarian cell lines. Pirker et al., "Anti-transferrin receptor antibody linked to *Pseudomonas* exotoxin; a model immunotoxin in human ovarian carcinoma cell lines", *Cancer Res.* 45:751-757 (1985). Anti-transferrin monoclonal antibodies that inhibit the binding of transferrin to the transferrin receptor are the subject of U.S. Patent 4,434,156. The anti-transferrin monoclonal antibodies of the present invention are different from those disclosed in U.S. Patent 4,434,156. Although the anti-transferrin antibody of the present invention binds the transferrin receptor, it does not inhibit the binding of transferrin to the transferrin receptor. Schlom et al., U.S. Patent 4,522,918 discloses a method of producing monoclonal antibodies against certain human breast cancer tumors using soluble extracts of human breast cancer.

EP-A-0153114 lists a number of particular breast cancer-specific monoclonal antibodies, and refers to immunotoxin conjugates incorporating such antibodies. Similarly, Bjorn et al., *Cancer Research*, Vol 45 (March 1985), 1214-1221, also discloses breast cancer-specific antibodies, including some antibodies referred to herein. Bjorn et al. does not, however, disclose ovarian cancer tissue-binding ability for such antibodies.

A principal aspect of the invention is an immunotoxin which comprises a cytotoxic moiety and an antigen binding portion selected from the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody which binds human ovarian cancer tissue and is selected from those obtainable from IVI 10068, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10064, HB 8692 and IVI 10084 said immunotoxin having at least one capability selected from:

a cytotoxicity ID<sub>50</sub> of about 10 nM or less against human ovarian cancer cells; retarding the rate of growth of tumours comprised of human ovarian cancer cells carried by a mammal when said mammal is treated with said immunotoxin; or extending the survival time of a mammal bearing a tumour comprised of human ovarian cancer cells when said mammal is treated with said immunotoxin.

Another aspect of the invention is the use of an antigen binding moiety selected from the group consisting of the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody selected from those obtainable from IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 and IVI 10084 in the manufacture of a medicament for use against human ovarian cancer by the provision of an immunotoxin comprising said antigen binding moiety and a cytotoxic moiety.

Yet another aspect of the invention is a formulation for retarding the growth of tumors comprised of human ovarian cancer cells or for killing human ovarian cancer cells comprising an immunotoxin of the invention formulated for such use.

Another aspect of the invention is an immunotoxin as defined above for use in the treatment of disease.

The invention also includes the use of an immunotoxin comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody selected from those obtainable from IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 and IVI 10084 in producing a formulation for retarding the growth of tumours comprised of human ovarian cancer cells or for killing human ovarian cancer cells.

Also within the invention is a method of making an immunotoxin as defined above comprising conjugating or linking an antigen binding portion and a cytotoxic moiety as defined above.

As used herein, the term "monoclonal antibody" means an antibody composition having a homogeneous antibody population. It is not intended to be limited as regards the source of the antibody or the

manner in which it is made.

As used herein the term "antigen binding portion" of a monoclonal antibody means the portion of the monoclonal antibody that binds an antigen to which the monoclonal antibody is specific. In general, such antibody binding portions of the monoclonal encompass the Fab, Fab' and F(ab')<sub>2</sub> regions or fragments of the immunoglobulin molecule. Fab, Fab' and F(ab')<sub>2</sub> regions of an immunoglobulin may be generated by enzymatic digestion of the monoclonal antibodies using techniques well known to those skilled in the art. Fab fragments may be generated by digesting the monoclonal antibody with papain and contacting the digest with a reducing agent to reductively cleave disulfide bonds. Fab' fragments may be obtained by digesting the antibody with pepsin and reductive cleavage of the fragment so produced with a reducing agent. In the absence of reductive cleavage, enzymatic digestion of the monoclonal with pepsin produces F-(ab')<sub>2</sub> fragments.

As used herein with regard to monoclonal antibody-producing hybridomas the term "progeny" is intended to include all derivatives, issue, and offspring of the parent hybridoma that produce the monoclonal anti-human ovarian cancer antibody produced by the parent, regardless of generation or karyotypic identity.

As used herein with respect to the exemplified murine monoclonal antibodies against human ovarian cancer, the term "functional equivalent" means a monoclonal antibody that: (a) binds to the same antigen or epitope as an exemplified monoclonal antibody as determined by immunoprecipitation or sandwich assay; (b) binds human ovarian cancer tissue frozen sections; (c) has a selectivity equal to or less than 0.11; (d) has a G or M isotype, and (e) when conjugated to a cytotoxic moiety forms an immunotoxin which (i) extends the survival of a mammal bearing human ovarian cancer cells when administered to such mammal or (ii) retards the growth of human ovarian cells in a mammal bearing such cells when administered to such a mammal or (iii) is cytotoxic to human ovarian cancer cells when such cells are contacted with the immunotoxin.

As described above, the term "functional equivalent" as used herein includes five criteria. The first of these criteria, binding to the same antigen or epitope as an exemplified monoclonal antibody may be demonstrated by experiments which show crossblocking of an exemplified monoclonal antibody by the functionally equivalent monoclonal antibody. Crossblocking occurs as a result of an antibody binding to the same epitope on an antigen as that bound by one of the exemplified antibodies, or as a result of an antibody binding to a different epitope which is so closely situated on the same antigen that binding of an antibody to one epitope blocks the binding of an antibody to the second epitope. Crossblocking thus is one of the criteria by which one can determine that a functionally equivalent monoclonal antibody binds to the same antigen or epitope as an exemplified monoclonal antibody.

So-called "sandwich" assays are another method for determining whether an antibody binds the same antigen or epitope. In these assays, a first monoclonal antibody is bound to a support, for example, the surface of a titre plate well. After treatment to prevent nonspecific binding, a highly solubilized antigen preparation is added to the bound antibody. Subsequently, a second antibody, having a detectable label, for example, a fluorescent dye, is added. If the second antibody binds to the antigen, a different epitope specificity or multiple copies of the same epitope on the same antigen is indicated. If the second antibody fails to bind, either the same epitope specificity or different antigen specificity is indicated. The results of both the crossblocking and sandwich assay are further defined by a second series of tests such as immune precipitation or Western blotting to show that the antigen bound by both antibodies has the same molecular weight.

The immunotoxins according to the invention are conjugates of the antigen binding portion of the monoclonal antibody and a cytotoxic moiety. The cytotoxic moiety of the immunotoxin may be a cytotoxic drug or an enzymatically active toxin of bacterial, fungal or plant origin, or an enzymatically active polypeptide chain or fragment ("A chain") of such a toxin. Enzymatically active toxins and fragments thereof are preferred and are exemplified by diphtheria toxin A fragment, nonbinding active fragments of diphtheria toxin, exotoxin A (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alphasarcin, certain *Aleurites fordii* proteins, certain *Dianthin* proteins, *Phytolacca americana* proteins (PAP, PAPII and PAP-S), *Momordica charantia* inhibitor, curcin, crotin, *Saponaria officinalis* inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and enomycin. Ricin A chain, *Pseudomonas aeruginosa* exotoxin A and PAP are preferred.

Conjugates may be made using a variety of bifunctional protein coupling agents. Examples of such reagents are N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters such as dimethyl adipimidate \* HCl, active esters such as disuccinimidyl suberate, aldehydes such as glutaraldehyde, bis-azido compounds such as bis(p-diazoniumbenzoyl)ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate, and bis-active fluorine compounds such as 1,5-difluoro-2,4-dinitrobenzene.

The enzymatically active polypeptide of the immunotoxins according to the invention may be recombinantly produced. Recombinantly produced ricin toxin A chain (rRTA) may be produced in accordance with the methods disclosed in PCT W085/03508 published August 15, 1985. Recombinantly produced diphtheria toxin A chain and non-binding active fragments thereof are also described in PCT W085/03508 published August 15, 1985.

When used to kill human ovarian cancer cells *in vitro* for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a concentration of at least about 10 nM. The formulation and mode of administration for *in vitro* use are not critical. Aqueous formulations that are compatible with the culture or perfusion medium will normally be used. Cytotoxicity may be read by conventional techniques such as dye exclusion or inhibition of colony formation in a clonogenic assay to determine the presence of an ovarian cancer tumor that is susceptible to treatment with the immunotoxin of interest.

When used *in vivo* for therapy, the immunotoxins are administered to the patient in therapeutically effective amounts (i.e., amounts that eliminate or reduce or retard the increase of the patient's tumor burden). They will normally be administered parenterally, preferably intraperitoneally (IP). The dose and dosage regimen will depend upon the nature of the cancer (primary or metastatic) and its population, the characteristics of the particular immunotoxin, e.g., its therapeutic index, the patient, and the patient's history. The amount of immunotoxin administered (IP) will typically be in the range of about 0.01 to about 100 mg/kg and preferably between 0.01 mg/kg and 10mg/kg of patient weight.

For parenteral administration the immunotoxins will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic and nontherapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The immunotoxin will typically be formulated in such vehicles at concentrations of about 0.01 mg/ml to 100 mg/ml.

Cytotoxic radiopharmaceuticals for treating ovarian cancer may be made by conjugating high linear energy transfer (LET) emitting isotopes (e.g., Y, Pr) to the antibodies. The term "cytotoxic moiety" as used herein is intended to include such isotopes.

The antibody-producing fusion partners that are used to make the hybridomas used to produce the materials of this invention are generated by immunizing mice with live human breast cancer cells or membrane extracts made therefrom. The mice are inoculated intraperitoneally with an immunogenic amount of the cells or extract and then boosted with similar amounts of the immunogen. Spleens are collected from the immunized mice a few days after the final boost and a cell suspension is prepared therefrom for use in the fusion.

Hybridomas are prepared from the splenocytes and a murine tumor partner using the general somatic cell hybridization technique of Kohler, B. and Milstein, C., *Nature* (1975) 256:495-497 as modified by Buck, D. W., et al, *In Vitro* (1982) 18:377-381. Available murine myeloma lines, such as those from the Salk Institute, Cell Distribution Center, San Diego, California, USA, may be used in the hybridization. Basically, the technique involves fusing the tumor cells and splenocytes using a fusogen such as polyethylene glycol. After the fusion, the cells are separated from the fusion medium and grown in a selective growth medium, such as HAT medium, to eliminate unhybridized parent cells. The hybridomas are expanded, if desired, and supernatants are assayed for anti-human breast cancer activity by conventional immunoassay procedures (e.g., radioimmunoassay, enzyme immunoassay, or fluorescence immunoassay) using the immunizing agent (breast cancer cells or membrane extract) as antigen. Positive clones are characterized further to determine whether they meet the criteria of the antibodies according to the invention.

Hybridomas that produce such antibodies may be grown *in vitro* or *in vivo* using known procedures. Preferably the hybridomas are maintained as ascites in mice. The monoclonal antibodies may be isolated from the culture media or body fluids, as the case may be, by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis, chromatography, and ultrafiltration, if desired.

The important characteristics of the monoclonal antibodies are (1) their immunoglobulin class, (2) their ability to bind human ovarian cancer tissue, (3) their selectivity as defined further hereinbelow (4) their usefulness in making effective anti-human ovarian cancer immunotoxins which are either cytotoxic to human ovarian cancer cells, or extend the survival of mammals carrying human ovarian cancer cells, or retard the growth of human ovarian cancer cells in animals bearing such cells. The monoclonal antibodies useful in making the immunotoxins according to the invention were initially identified as monoclonal antibodies within a group of anti-breast cancer monoclonal antibodies.

In selecting the antibodies used in this invention, approximately 22,000 growing hybridoma cultures were initially screened against the immunizing breast tumor membranes or cell line, a panel of seven normal tissue membranes, a fibroblast cell line and a breast tumor frozen section. Clones that reacted with the neoplastic materials, but not the normal materials, were identified in this initial screen and chosen for isotyping and additional screening for selectivity and range. The additional screening involved: sixteen normal tissue sections, five normal blood cell types, eleven nonbreast neoplasm sections, twenty-one breast cancer sections and fourteen breast cancer cell lines. In the additional screening, a number of monoclonal antibodies bound ovarian carcinoma tissue sections strongly but did not appear to bind to normal ovarian tissue sections.

For purposes of this patent application, specificity and selectivity are used interchangeably and are defined as the sum of the number of substructures stained in sixteen normal tissue frozen sections and the number of blood cell types bound, divided by the sum of the total number of substructures bound by any of the monoclonal antibodies in all the tissues on which the monoclonal antibodies were tested and five blood cell types tested. 123 Substructures and five blood cell types were counted in the tests. Antibodies were deemed to be appropriate candidates for ovarian cancer immunotoxin purposes if they have a selectivity equal to or less than 0.11 and bound to human ovarian cancer tissues.

Antibodies produced by one of the hybridomas were found to recognize a 200 K dalton antigen. Antibodies of two of the hybridomas bound to a 42 K dalton antigen. Four bound to one or more high molecular weight mucins (HMW) and two bound to transferrin receptors in the form of a 95 K dalton antigen. Two bound to the same epitope of a 55 K dalton antigen. All antigen weights mentioned herein were determined by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis under reducing conditions using procedures known in the art.

Further details of the characterization of these antibodies are provided in the examples below.

Fresh postsurgical human breast cancer tissue and a variety of normal tissues were used to prepare membrane extracts by homogenization and discontinuous sucrose gradient centrifugation. Human breast cancer cell lines were obtained from the Breast Cancer Task Force, the American Type Culture Collection (ATCC), and from Dr. Jorgen Fogh at Memorial Sloan Kettering. The cells were maintained and passaged as recommended by the Breast Cancer Task Force, the ATCC and Dr. Fogh. For immunizations, either membrane extract containing 100 µg of protein (Lowry assay) or ten million live breast cancer cells were inoculated intra-peritoneally into five week old Balb/c mice. The mice were boosted identically twice at monthly intervals. Three days after the last boost, the spleens were removed for cell fusion.

Somatic cell hybrids were prepared by the method of Buck, D. W., et al, supra, using the murine myeloma line Sp-2/O/Ag14. All hybridoma cell lines were cloned by limiting dilution. Half of the fusions employed splenocytes from mice immunized with breast cancer membrane extracts and half used splenocytes from mice immunized with live breast cancer cell lines. Eighty-three thousand four hundred twenty-four wells were generated from those fusions, of which 22,459 exhibited hybridoma growth.

Hybridoma supernatant was assayed for reactive antibody in either a solid phase enzyme-linked immunosorbent assay (ELISA) with the immunizing breast cancer membrane extract or an indirect immunofluorescence assay with the immunizing breast cancer cell line. For the solid phase membrane ELISA, 40 µl of 0.1 mg/ml breast cancer membrane protein were placed in polyvinyl chloride (PVC) microtiter wells for 12 hours at 4°C. The extract was aspirated and the wells washed with phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA). The wells were then incubated with 45 µl of a 1:10 dilution of hybridoma supernatant. The diluent was media with 25 mM of a buffer, 10% bovine serum, and 0.1% sodium azide. After 30 minutes at room temperature, the wells were again washed and incubated 45 minutes at 37°C with a 1:200 dilution of peroxidase conjugated goat anti-mouse IgG. The diluent was PBS. The wells were then washed with PBS and reacted with 200 µl of 1,2-azino-di(3-ethylbenzthiazoline sulphonic acid) in 0.1 M sodium citrate buffer pH 4.2 for 30 minutes at room temperature. Optical density was measured at 405 nm on a MicroElisa Reader. For each experiment a positive control, anti-beta 2 microglobulin at 5 µg/ml, was reacted with normal human kidney membrane. This gave an optical density of  $1.0 \pm 0.1$  (standard deviation). The background was  $0 \pm 0.1$  optical density units (O.D.) using media without mouse monoclonal antibody. Wells that gave a reaction on the breast cancer membrane extract of greater than 0.7 O.D. were saved.

For the indirect immunofluorescence cell line assay 100,000 breast cancer cells of the immunizing cell line were placed overnight with appropriate media in each chamber of a set of eight chambered slides. Similarly, 100,000 fibroblast cells from cell line CC95 were incubated overnight in chambered slide wells. The cells were washed with PBS containing 1% BSA. The wells, both breast cancer and fibroblast, were incubated for 30 minutes at 4°C with 1:10 dilutions of hybridoma supernatant. The cells were again washed and incubated 30 minutes at 4°C with a 1:50 dilution of fluorescein isothiocyanate (FITC)-conjugated goat

F(ab')<sub>2</sub> anti-mouse Ig. The cells were washed three times, fixed in 1.5% formaldehyde in PBS for five minutes, chambers removed and rinsed in PBS. The slides were then mounted in a composition containing polyvinyl alcohol, glycerol, buffers and a preservative and examined with a fluorescence microscope. Hybridoma wells showing strong fluorescent binding to the breast cancer cells but no fluorescent binding to fibroblasts were saved. Five thousand one hundred fifty-six hybridoma wells revealed breast cancer reactivity in the initial screen.

Supernatants from the 5156 positive wells were then tested in solid phase ELISA with seven normal tissue membrane extracts (liver, lung, colon, stomach, kidney, tonsil, and spleen). Any supernatant giving an ELISA O.D. greater than 0.3 was discarded. One thousand one hundred one of the supernatants were found to be unreactive with the normal tissue extracts.

The 1101 hybridoma supernatants were tested on frozen sections of human breast carcinoma tissues. Six micron sections were attached to slides, fixed 10 minutes in acetone at 4°C, dried 10 minutes at room temperature, washed with PBS, blocked with horse serum and incubated 20 minutes at room temperature with 100 µl neat hybridoma supernatant. The slides were washed with PBS, and finally incubated 20 minutes at 37°C with a 1:50 dilution of peroxidase conjugated rabbit anti-mouse Ig, washed again with PBS, and finally incubated 7.5 minutes at 37°C with 0.5 mg/ml diaminobenzidine in 0.05 M Tris buffer pH 7.2 containing 0.01% hydrogen peroxide. The slides were stained with hematoxylin, dehydrated and mounted in a medium containing 35.9% methyl/n-butylmethacrylate copolymer, 7.1% butyl benzyl phthalate, and 0.3% 2,6-di-tert-butyl-p-cresol. One hundred twenty-four wells yielded breast cancer selective binding and were cloned.

Immunoglobulin class and subclass of the monoclonal breast cancer selective antibodies were determined by an immunodot assay essentially the same as that described in McDougal et al. *J. Immunol. Meth.* 63:281-290 (1983). Antibodies were also internally labeled by growing 2-3 x 10<sup>6</sup> hybridoma cells for four hours in methionine-free medium containing 0.2 µCi <sup>35</sup>S methionine. <sup>35</sup>S-labeled antibodies were immunoprecipitated with fixed staphylococcus A cells, or with fixed staphylococcus A cells precoated with rabbit anti-mouse immunoglobulin, and the immunoprecipitates were analyzed by SDS-PAGE to determine antibody light and heavy chain mobility, lack of extra chains, and the ability of each antibody to bind staphylococcal protein A.

The antibodies were expanded *in vivo*. Balb/c or F1 (C57B/6 x Balb/c) mice were primed with 0.5 ml pristane intraperitoneally (ip) and after 10-14 days inoculated with one million log phase hybridoma cells in PBS. Ascites fluid was stored at -70°C and thawed and filtered through a 0.8 micron filter unit before further purification.

Some IgG antibodies that bound staphylococcal protein A were purified by affinity chromatography on protein A-chromatographic resin containing either agarose, dextran and/or acrylamide with pH step gradient elution. IgG antibodies that did not bind protein A were precipitated by addition of ammonium sulfate to 40% saturation at 0°C. or by binding to DEAE or Affigel™ (Biorad, Richmond, California). Alternatively, IgG antibodies were purified by chromatography using a Sephacryl S-200 column, followed by DEAE cellulose as described. The precipitates were redissolved in PBS, dialysed to 20 mM Tris pH 7.2 and chromatographed on a 1.6 x 50 cm column of diethylaminoethyl cellulose (DEAE) eluting with a 1.5 liter 0-600 mM NaCl gradient at 4°C at a flow rate of 1 ml/min. In each case, column fractions were monitored by SDS-PAGE and the purest antibody fractions were pooled, concentrated to 1-3 mg/ml, dialysed to PBS/0.02% NaN<sub>3</sub>, and stored at 4°C.

IgM antibodies were purified by gel filtration material on a 2.6 x 40 cm column of Sephacryl S-300 or other gel filtration or resin containing agarose, dextran and/or acrylamide, eluting with PBS/0.01% sodium azide at room temperature at a flow rate of 1ml/min.

In order to evaluate their selectivity, the purified antibodies were tested by immunoperoxidase section staining on sections of sixteen normal tissues, and by immunofluorescent cell sorting on five blood cell types. Immunoperoxidase staining was performed as above except that known dilutions of purified antibodies in PBS in the range of 1-40 µg/ml were used instead of hybridoma supernatants. The pure antibodies were first titrated to find the minimal concentration giving strong immunoperoxidase staining on breast cancer sections and then used at the concentration for the normal tissue tests. No normal ovarian tissue showed detectable binding.

Peripheral blood cells (platelets, lymphocytes, red blood cells, granulocytes, and monocytes) were prepared by centrifugation using a medium which separated monocytes from polymorphonuclear leukocytes. The cells were reacted with antibody at the optimal concentration determined above for 30 minutes at 4°C, washed, reacted with a 1:50 dilution of fluorescein isothiocyanate-conjugated goat anti-mouse Ig for 30 minutes at 4°C, washed again and examined in a cell sorter. The wash buffer and diluents were PBS with 1% gelatin and 0.02% sodium azide. The cell sorter was equipped with a 76 micron nozzle and a one

The binding behaviors on normal tissue sections of the antibodies useful in the immunotoxins according to the invention are reported in Table 1 below. The following abbreviations are used to denote structures bound by the antibodies: Ac, acini; G, glands; T, tubules; D, ducts; L, lumen; W, sweat glands; E, epithelium; S, sebaceous glands; Gr, granulocytes; Mk, megakaryocytes; M, macrophage; Ly, lymphocytes; Bl, Basal layer; Fe, focal epithelium; A, aveolar lining cells; B, Bowman's capsule; Mu, muscle; I, islets; X, ganglia/nerve; V, blood vessel; and H, hair follicle. Selectivity was quantified as described hereinabove. The binding behavior of the antibodies on peripheral blood cells is reported in Table 2. The selectivity of the monoclonal antibodies is set out in Table 3.

15  
20  
25  
30  
35  
40  
45  
50  
55

[illegible]

TABLE 2

BLOOD CELL BINDINGS OF OVARIAN MABS					
MAB	RBC	PLATELET	LYMPHOCYTE	GRANULOCYTE	MONOCYTE
1 2G3	0	0	0	0	0
2 9C6	0	0	0	0	0
3 33F8	0	0	0	0	0
4 44B2	0	0	0	0	0
5 44F4	0	0	0	2	0
6 120H7	0	0	0	0	0
7 200F9	0	0	0	0	0
8 204F4	0	0	0	0	1
9 219F3	0	0	0	0	0
10 245E7	0	0	0	0	0
11 260F9	0	0	0	0	0
12 266B2	0	0	0	0	0
13 280D11	0	0	0	2	0
14 317G5	0	0	0	0	0
15 369F10	0	0	0	0	0
16 388D4	0	0	0	0	0
17 421E8	0	0	0	0	0
18 451C3	0	0	0	0	0
19 454A12	0	0	0	0	0
20 454C11	0	0	0	0	0
21 650E2	0	0	0	0	0
22 788G6	0	0	0	0	0
23 871E3	0	0	0	0	0



TABLE 3

5	TISSUE SELECTIVITY OF OVARIAN MABS			
	MAB	BLOOD CELLS BOUND	NORMAL TISSUE SUBSTRUCTURES BOUND/NORMAL TISSUE SUBSTRUCTURES AND BLOOD CELLS	SELECTIVITY
10	1 2G3	0 / 5	9 / 128	0.070
	2 9C6	0 / 5	6 / 128	0.047
	3 33F8	0 / 5	7 / 128	0.055
15	4 44B2	0 / 5	3 / 128	0.023
	5 44F4	1 / 5	12 / 128	0.094
	6 120H7	0 / 5	5 / 128	0.039
20	7 200F9	0 / 5	3 / 128	0.023
	8 204F4	1 / 5	11 / 128	0.086
	9 219F3	0 / 5	10 / 128	0.078
25	10 245E7	0 / 5	9 / 128	0.070
	11 260F9	0 / 5	11 / 128	0.086
	12 266B2	0 / 5	9 / 128	0.070
30	13 280D11	1 / 5	12 / 128	0.094
	14 317G5	0 / 5	6 / 128	0.047
	15 369F10	0 / 5	2 / 128	0.016
35	16 388D4	0 / 5	13 / 128	0.102
	17 421E8	0 / 5	6 / 128	0.047
	18 451C3	0 / 5	6 / 128	0.047
40	19 454A12	0 / 5	4 / 128	0.031
	20 454C11	0 / 5	10 / 128	0.078
	21 650E2	0 / 5	8 / 128	0.063
45	22 788G6	0 / 5	2 / 128	0.016
	23 871E3	0 / 5	11 / 128	0.086

The antibodies were tested by immunoperoxidase staining on eleven non-breast malignancies. The results for the antibodies are reported in Table 4 below.

TABLE 4

MAB	COLON	LUNG	PRO-STATE	PAN-CREAS	UTERUS	LYM-PHOMA	STO-MACH	BLADDER	ESO-PHAGUS	MELA-NOMA	OVA-RIAN
1 2G3	2	0	2	0	2	0	2	0	0	0	2
2 9C6	1	0	0	0	2	1	0	0	0	0	1
3 33F8	0	1	0	0	1	0	0	0	0	0	1
4 44B2	0	0	0	0	0	0	0	1	0	0	1
5 44F4	1	0	1	0	1	0	0	0	0	0	2
6 120H7	0	0	2	0	1	1	0	0	0	0	2
7 200F9	0	1	0	0	0	0	0	0	0	0	1
8 204F4	0	1	2	1	2	1	0	0	0	0	2
9 219F3	0	0	1	0	1	1	0	0	0	0	1
10 245E7	0	2	2	2	2	2	0	0	0	0	2
11 260F9	0	0	1	1	1	0	0	0	1	0	2
12 268B2	0	1	1	1	1	0	1	0	1	0	1
13 280D11	0	0	1	1	1	2	0	0	0	0	2
14 317G5	1	1	0	0	1	0	0	0	0	0	1
15 369F10	0	1	1	1	0	0	0	0	0	0	2
16 38804	1	1	2	1	2	0	0	0	1	1	1
17 421E8	1	1	1	1	1	0	0	0	1	1	1
18 451C3	1	1	1	1	2	1	2	1	2	1	1
19 454A12	0	0	0	1	2	0	1	1	2	2	1
20 454C11	0	0	1	1	2	0	0	0	0	0	1
21 650E2	2	2	2	2	2	0	0	0	0	0	2
22 788G6	0	2	0	0	0	0	0	0	0	0	2
23 871E3	0	2	0	1	0	0	0	0	0	0	1

Several of the antibodies were iodinated and tested for binding to MCF-7, CAMA1, SKBR3 or ZR7530 cells. The antibodies were labeled with  $^{125}\text{I}$  using chloramine T or Iodogen<sup>TM</sup> to a specific activity of approximately 5-10  $\mu\text{Ci}/\mu\text{g}$ . To determine immunoradiochemical purity, 100,000 cpm of two of the labeled antibodies in 0.5 ml fetal calf serum was serially absorbed with five aliquots of target cells for 15 minutes at 0°C (generally 4,000,000 cells per aliquot), and the remaining radioactivity in the supernatant after each absorption was determined.

For measurements of association constants, known concentrations of labeled and unlabeled monoclonal antibodies were incubated with target cells in fetal calf serum for 15 minutes on ice. Aliquots of the cell/antibody mix were then counted in a gamma counter or filtered through Microfold filter plates (V & P Scientific) and the filters counted. To account for unbound antibody retained in liquid on the filters, controls containing the same concentrations of antibody but no cells were done in parallel. Association constants

and antigen copy number per target are calculated from the affinity test results and are reported in Table 5 below.

TABLE 5

AFFINITY AND ANTIGEN COPY NUMBER OF OVARIAN MABS			
MAB	n	Ka	CELL LINE
1 2G3	3700000	9.1x10 <sup>5</sup>	MCF7
2 9C6			
3 33F8			
4 44B2			
5 44F4	2100000	5.3x10 <sup>5</sup>	MCF7
6 120H7	210000	2x10 <sup>7</sup>	MCF7
7 200F9	3200000	8.0x10 <sup>5</sup>	MCF7
8 204F4			
9 219F3			
10 245E7			
11 260F9	310000	5.6x10 <sup>7</sup>	MCF7
12 266B2	80000	2.7x10 <sup>8</sup>	MCF7
13 280D11	390000	8.8x10 <sup>5</sup>	MCF7
14 317G5	3200000	1.6x10 <sup>5</sup>	CAMA1
15 369F10	400000	4x10 <sup>8</sup>	MCF7
16 388D4			
17 421E8			
18 451C3			
19 454A12	470000	1.2x10 <sup>8</sup>	MCF7
20 454C11	390000	4.8x10 <sup>7</sup>	ZR7530
21 650E2	390000	4.8x10 <sup>7</sup>	ZR7530
22 788G6			
23 871E3			

In order to identify the antigens recognized by the monoclonal antibodies, immunoprecipitation of the antigens was carried out according to the following method. Eight mm diameter polystyrene balls (Precision Plastic Ball Co.) were covered with 10% fuming nitric acid in glacial acetic acid and were incubated for three hours in a 50°C water bath. Following the acid treatment, the balls were rinsed three times with distilled water, covered with 1% sodium dithionite in 0.1 M NaOH and incubated three hours in a 50°C water bath. The balls were again rinsed three times with distilled water, covered with 0.1% 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EUAC), 0.2% suberic acid (suberic acid dissolved in dimethylformamide) and incubated overnight at room temperature. The balls were rinsed three times with distilled water, and marked for identification.

Purified monoclonal antibodies were diluted 0.2 mg/ml in 2-(N-morpholino)ethane sulfonic acid buffer, and the previously treated and marked polystyrene balls were placed in individual tubes and covered with 450 microliters diluted antibody and 50 microliters of fresh 1% EDAC. Tubes were capped and incubated at 25°C for 24 hours. Following this incubation, the balls were rinsed twice with PBS and were either used fresh or were stored for several days at 4°C before use.

Freshly labeled target cell extracts were prepared from human breast cancer cell lines labeled with <sup>125</sup>I by the lactoperoxidase method of Marchalonis, J., "An Enzymic Method for the Trace Iodination of Immunoglobulins and other Proteins", Biochem. J. 113:299-305 (1969), or with <sup>35</sup>S by growth in <sup>35</sup>S methionine. The labeled cells were dissolved in solubilization buffer (1% (v/v) Triton X-100, 150 mM NaCl, 5 mM EDTA, 25 mM Tris-HCl, pH 7.5). Four parts of labeled extract were mixed in a vessel with one part solubilization buffer containing 50 mg/ml bovine serum albumin, to give a final concentration of 10 mg/ml BSA. The balls coated with monoclonal antibody were added to the vessel and were incubated four hours on ice with shaking. Labelled antigen was pipetted from the vessel and the balls were rinsed four times with solubilization buffer. The balls were then removed, placed in individual tubes with 100 microliter Laemmli SDS gel sample buffer, and were incubated three minutes in boiling water. The balls were removed and the samples were run on an SDS gel with appropriate standards.

Immunoprecipitation tests on the antibodies indicated that eight of them (2G3, 120H7, 200F9, 204F4, 245E7, 369F10, 788G6, and 871E3) all bind to high molecular weight mucins (HMW). Two (260F9 and 266B2) bind to the same epitope of a 55 Kd glycoprotein antigen. Two (317G5 and 650E2) bind to a 42 Kd antigen. Two antibodies (451C3 and 454A12) bound to transferrin receptors in the form of a 95 Kd antigen. Neither 451C3 nor 454A12 blocked binding of transferrin to the receptor. The antigen binding characteristics of the monoclonal antibodies that were tested are summarized in Table 6.

TABLE 6

ANTIGENS RECOGNIZED BY OVARIAN MONOCLONAL ANTIBODIES	
MAB	ANTIGEN
1 2G3	HMW
2 9C6	75 Kd
3 33F8	66 Kd
4 44B2	
5 44F4	18, 39, 72, 81, 175 Kd (all diffuse bands)
6 120H7	HMW
7 200F9	HMW
8 204F4	HMW
9 219F3	
10 245E7	HMW
11 260F9	55 Kd
12 266B2	55 Kd
13 280D11	
14 317G5	42 Kd
15 369F10	HMW
16 388D4	
17 421E8	
18 451C3	95 Kd (TRANSFERRIN RECEPTOR)
19 454A12	95 Kd (TRANSFERRIN RECEPTOR)
20 454C11	200 Kd
21 650E2	42 Kd
22 788G6	HMW
23 871E3	HMW

Antibody isotype was determined as follows: A grid of 5-mm squares is lightly drawn in pencil on the nitrocellulose sheet and 1-ml droplets of antiisotype sera (Litton Bionetics, Kensington, Maryland, rabbit antisera to mouse  $\kappa$ ,  $\lambda$ ,  $\alpha$ ,  $\gamma$ 1,  $\gamma$ 2a,  $\gamma$ 2b,  $\gamma$ 3, and  $\mu$  chains) are applied so that each row of squares receives one spot of each heavy and light chain reagent. The sheet is incubated one hour at room temperature in a moist chamber, rinsed quickly in PBS-BSA, containing 1% (w/v), and left overnight in PBS-BSA at 4°C. Strips are cut apart with a scissors and may be stored at 4°C in PBS-BSA containing 0.02% sodium azide. Alternatively, strips may be air-dried and stored desiccated at 4°C. A series of small tubes is prepared containing 3 ml hybridoma culture supernatant or supernatant diluted with PBS-BSA. 1:10 dilutions are generally successful; and some supernatants can be diluted as much as 1:200. A nitrocellulose strip is incubated in each tube for one hour at room temperature. The strips are rinsed three times in PBS-BSA and incubated for one hour at room temperature in diluted rabbit anti-mouse-horseradish peroxidase. The strips are rinsed twice in PBS-BSA and twice in Tris buffer. The strips are placed in Tris buffer containing diaminobenzidine and hydrogen peroxide until sufficient color develops on the anti-isotype spots (usually 3-4 minutes). The antibody isotypes are indicated in Table 7.

TABLE 7

ISOTYPE OF OVARIAN MONOCLONAL ANTIBODIES	
MAB	ISOTYPE
1 2G3	G1
2 9C6	M
3 33F8	G1
4 44B2	G1
5 44F4	G3
6 120H7	M
7 200F9	G1
8 204F4	M
9 219F3	G1
10 245E7	G1
11 260F9	G1
12 266B2	G1
13 280D11	G1
14 317G5	G1
15 369F10	M
16 388D4	G1
17 421E8	G1
18 451C3	G1
19 454A12	G1
20 454C11	G2A
21 650E2	G1
22 788G6	G1
23 871E3	M

The antibodies were treated with SPDP as described by Bjorn et al., "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," *Cancer Res.* 45:1214-1221 (1985) and Carlsson, J. et al., *Biochem. J.* (1978) 173:723-737 or with iminothiolane (IT) and were conjugated to ricin toxin A chain (RTA) to make the claimed immunotoxins.

SPDP (20 mM in ethanol) was added in a 20-fold molar excess to antibody and following a 30 min incubation at room temperature, the unreacted SPDP was removed by dialysis against PBS. The extent of derivatization was determined by measuring the release of pyridine-2-thione at 343 nm after reduction with dithiothreitol (DTT). Depending on the antibody, three to eight lysine amino acid groups (per antibody molecule) were converted to the pyridyl-disulfide derivative.

The SPDP-treated antibodies were conjugated with RTA. Immediately prior to conjugation, the RTA was reduced with 50 mM DTT, then desalted on a column of chromatographic resin containing agarose, dextran and/or acrylamide to remove DTT from protein. Reduced RTA was added in a three- to five-fold molar excess over pyridyl-disulfide antibody. A typical reaction mixture (1 ml) consisted of 7  $\mu$ M antibody and 30  $\mu$ M RTA. The reaction was allowed to proceed overnight at 4°C. The extent of conjugation of RTA to antibody was determined spectrophotometrically by measuring the release of pyridine-2-thione. On the average, conjugates contained two to three RTA molecules per antibody molecule. This was confirmed by nonreducing SDS-PAGE gels (7.5%), which also revealed that the typical conjugate preparation contained 10%-30% free antibody.

The conjugate mixture was chromatographed on a HPLC size exclusion column to separate conjugates from residual unreacted RTA. The column was equilibrated in 0.1 sodium sulfate/0.02 M sodium phosphate pH 6.8. Conjugate mixture (0.7 ml) was injected, then chromatographed at a flow rate of 1 ml/min (room temperature). Fractions of 0.5 ml were collected and the peak conjugate fractions were pooled and filter sterilized prior to cytotoxicity testing.

Approximately 30 mg/ml antibody in 0.10 M Na phosphate, 0.001 M Na EDTA, pH 8.0 (hereafter referred to as P-EDTA buffer) is reacted with 1 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) at room temperature for about 15 min and then chilled to 0°C in an ice bath. Enough IT is added to this solution to give an average of 2.5 IT molecules/antibody molecule, and the resulting solution is dialysed at 0-5°C against three 100-fold excess volumes of P-EDTA buffer.

RTA, normally stored in P-EDTA containing 1 mM DTT, is ultrafiltered to a concentration between 10 and 15 mg/ml and dialyzed at 0-5°C against three 100-fold excess volumes of P-EDTA. Enough RTA is added to the derivatized antibody to give an average of 1.0-1.2 free thiols on RTA per blocked thiol on derivatized antibody. This mixture is incubated at room temperature for 2 hrs.

5 The coupling reaction mixture is applied to a column of a chromatographic resin based on a blue dye (trysacryl blue) covalently coupled to a solid support, which mixture is then eluted with P-EDTA at room temperature. The column is scaled to contain approximately 2 ml of bed volume per mg of starting antibody. After an initial peak of unconjugated antibody has been eluted from the column, the elutant is switched to P-EDTA containing 1 M NaCl. Immunoconjugate and unreacted RTA are eluted in this buffer as  
10 a very sharp peak, which is pooled and dialyzed at 0-5°C against one 10-fold excess volume of 0.15 M Na phosphate, pH 7.1 (hereafter referred to as  $p_i$  buffer). The dialyzed protein is applied to a column of a size-exclusion gel at 0-5°C and eluted with buffer at a flow rate of 6 cm/hr. The column is scaled to contain at least 25 ml of bed volume/ml of applied protein. Immunoconjugate is eluted as a single peak, slightly after the excluded volume, baseline-resolved from following peaks of dimerized and monomeric RTA. The pooled  
15 immunoconjugate peak is ultrafiltered at 35 psi to a final concentration of 5.0 mg/ml and filter-sterilized.

The invention will be better understood in light of the following illustrative Examples.

#### Example I

20 Female athymic nude mice (Nu/Nu, strain Balb/C), weighing between 16 and 22 grams were used. NIH:OVCAR-3 ascites cells were obtained from carrier mice. The cells were washed twice in phosphate buffered saline (PBS) and resuspended in PBS at approximately 1 volume of cells to 2 volumes of PBS. Cell count was determined by counting in a haemocytometer. Cell viability was determined by trypan blue dye exclusion. Each animal was injected intraperitoneally with  $5 \times 10^7$  viable cells on day zero. Animals were  
25 injected with the immunotoxins on days 4, 7 and 10. The immunotoxin was usually admistered in 0.1ml PBS. Control animals were injected with 0.1ml PBS on the same schedule. Five animals were used for each dose of each immunotoxin tested and for the controls. Animals were observed daily. Effectiveness was determined by an increase in survival time relative to controls in each experiment or by less abdominal swelling due to retardation or the increase in tumor burden in treated animals as compared to controls  
30 having the same survival time.

The results are reported in Table 8. In Table 8, and the following tables, "Swelling Ind ex" is defined as follows: 0 = no abdominal distension; 1 = barely visible abdominal distension; 2 = moderate abdominal distension; and 3 = severe abdominal distension.

35

40

45

50

55

Experiment A

Test Material	Dose	#Surviving	Swelling Index	Mean Life Span
317G5-IT-RTA	50ug	0	-	49.8 +/- 10
	100ug	2	3	60.2 +/- 5.2
260F9-IT-RTA	50ug	0	-	25 +/- 1.4
	100ug	0	-	24.6 +/- 3.3
113F1-IT-RTA	25ug	0	3	32.2 +/-13.9
	50ug	0	-	29 +/-3.0
PBS Controls	0.1ml	0	-	29

Experiment B

Material	Dose	#Surviving (day 85)	Swelling Index	Mean Survival
PBS	-	0	3	48
454A12-IT-rRTA	25ug	1	2	>74
280D11-IT-RTA	50ug	1	2	>66
	100ug	2	2	>71
2G3-IT-RTA	50ug	0	3	30
	100ug	0	3	35

Example II

In the following example the experiment was run essentially as described in the previous example except that the animals were injected on days 4, 6 and 8. This example shows that the anti-tumor effect of immunotoxin 454A12-IT-rRTA is blocked when tumor bearing animals are treated with an excess of the monoclonal antibody 454A12 from which the immunotoxin is derived. MOPC21, an antibody which is not human ovarian tumor specific, when administered at excess with 454A12-IT-rRTA has no corresponding blocking effect.

TABLE 9

Material	Dose(ug)#	# Surviving (day 69)	Swelling Index	Survival (mean days)
PBS	-	0	3	41
454A12-IT-RTA	25	4	0	>69
454A12-IT-RTA + 454A12(500ug)	25	0	3	26
454A12-IT-RTA + MOPC21 (500ug)	25	3	1	>65
317G5-IT-RTA	50	2	0	>60
	100	4	0	>65

Example III

The procedure used in this experiment is essentially the same as Example I. This experiment shows that immunotoxins comprised of the Fab'2 fragment of 454A12 conjugated to RTA has antitumor activity comparable to 454A12-IT-RTA.

TABLE 10

Material	Dose(ug)#	# Surviving (day 34)	Swelling	Survival (mean days)
PBS	-	3	3	>34
454A12-IT-RTA	10	2	0	>34
454A12-IT-RTA	25	3	0	>39
454A12-IT-RTA	50	4	0	>39
454A12-RTA	10	3	0	>39
(Fab'2)	25	4	0	>39
	50	3	0	>34

#### Example IV

The following Example shows the in vitro cytotoxicity of Immunoconjugates against several ovarian cancer cell lines.

NIH:OVCAR-2, -3, -4, and -5 are isolates from the malignant ascites of patients with ovarian carcinoma. These cell lines have been previously described in the following references which are herein incorporated by reference. Hamilton et al., "Characterization of Human Ovarian Carcinoma Cell Lines (NIH:OVCAR-3) with Androgen and Estrogen Receptors" *Cancer Res* 43:5379-5389 (1983). Hamilton et al., "Experimental Model Systems of Ovarian Cancer: Applications to the Design and Evaluation of New Treatment Approaches" *Seminars in Oncology* 11:285-298 (1985). The ovarian cancer cell line A1847 was obtained from S. Aaronson (National Cancer Institute, Bethesda, Maryland). The ovarian cells were grown in RPMI medium 1640, 10% fetal bovine serum, 10  $\mu$ g/ml insulin and penicillin-streptomycin. KB cells were grown in Dulbecco's Modified Eagle Medium (DMEM), 10% calf serum, glutamine and penicillin-streptomycin. Tissue culture media, sera, glutamine and antibiotics were purchased from Grand Island Biological Co., Grand Island, NY, and insulin was obtained from Elanco Products Company, Indianapolis, IN. For protein synthesis inhibition assays, cells were plated at  $2 \times 10^5$  cells/35-mm dish one day prior to use. Before adding immunotoxins, cells were washed twice with DMEM containing bovine serum albumin (2 mg/ml) (DMEM-BSA). The listed immunotoxins were made by iminothiolane derivitization and conjugation to RTA as described hereinabove.

Inhibition of protein synthesis was used to measure the activity of the immunotoxins. Cells were incubated with DMEM-BSA containing various concentrations of immunotoxins at 37°C for 24 h and then assayed for incorporation of [ $^3$ H]leucine (New England Nuclear, Boston, MA; specific activity 140.8 Ci/mmol) into TCA-insoluble material as described in Pirker et al. "Anti-Transferrin Receptor Antibody Linked to Pseudomonas Exotoxin: A Model Immunotoxin in Human Ovarian Carcinoma Cell Lines" *Cancer* 45:751-757 (1985). Mean values of duplicates were expressed as a percentage of controls of the same cell line which did not receive immunotoxins. Immunoconjugates that gave 50% inhibition of protein synthesis as compared to untreated controls ( $ID_{50}$ ) of 10nM or less were considered to be effective.  $ID_{50}$  of the immunoconjugates tested are listed below in Table 11.



TABLE 11

IN VITRO CYTOTOXICITY ID <sub>50</sub> (nM)						
RTA CONJUGATE	OV-2	OV-3	OV-4	OV-5	A1847	KB
454A12	0.04	0.05	0.05	0.03	---	0.01
317G5	0.1	0.2	0.1	0.3	---	0.1-2
260F9	0.2	0.5	0.2	0.2	>5	140
113F1	---	2	---	---	---	---
280D11	>30	4	13	>20	>30	120
2G3	---	8	---	---	---	---
369F10	---	10	---	---	---	---
454C11	>5	>5	>5	>5	>5	>5
520C9	>5	---	---	---	---	---
245E7	>30	>30	>30	30	>30	>30

Example V

The immunoconjugates described in the immediately preceeding example were tested against NIH:OVCAR-3 cells. Cells were maintained in RPM1 medium 1640, 10% fetal bovine serum, 10 µg/ml insulin and penicillin-streptomycin. Cells were removed from the culture flasks by mild trypsin digestion or versene addition. The cell concentration was adjusted. 4 x 10<sup>5</sup> NIH:OVCAR-3 cells were suspended in 1 ml of medium and were added to 8-ml glass vials (ICN), followed by the addition of conjugate dilutions (in PBS containing bovine serum albumin, 100 µg/ml). After incubation at 37° for 22 hrs., the medium was aspirated, the monolayers were washed with PBS, and 0.5 ml methionine-free medium supplemented with 0.5 µCi L-[<sup>35</sup>S]methionine (Amersham; 1400 Ci/mmol) was added. After a 2-hr incubation at 37°, the medium was aspirated, and the cell monolayers were washed twice with 10% trichloroacetic acid containing methionine (1 mg/ml). The cells were dried, scintillation fluid was added, and the radioactivity was measured in a Packard CL/D liquid scintillation counter.

Inhibition of protein synthesis was calculated as the incorporation of TCA precipitable <sup>35</sup>S counts for each vial. Mean values were expressed as a percentage of controls of the same cell line that did not receive immunotoxins. ID<sub>50</sub>'s were determined as in the immediately preceeding example. The results are reported in the following Table 12.

TABLE 12

In Vitro Cytotoxicity vs. OVCAR-3	
CONJUGATE	ID <sub>50</sub> (nM)
454A12-RTA	0.05
454A12-RTA	0.2
454A12-(Fab') <sub>2</sub> -RTA	0.4
317G5-RTA	0.2
113F1-RTA	2
2G3-RTA	3
260F9-RTA	4
280D11-RTA	30
454C11-RTA	50
369F10-RTA	>56
245E7-RTA	>56
520C9-RTA	>112
MOPC21-RTA	>112
MOPC21-RTA	>80

### Example VI

This Example shows the cytotoxicity of immunoconjugates comprising the monoclonal antibodies described above and *Pseudomonas* exotoxin.

*Pseudomonas* exotoxin (PE) was a gift of Dr. S. Leppla (Ft. Detrick, Frederick, MD). PE may also be obtained commercially from Swiss Serum and Vaccine Institute, Berne, Switzerland. PE conjugates were constructed and purified by a modification of a method previously incorporated herein by reference. Pirker et al. (1985). PE (30 nmol) was reacted with 5000 nmol 2-iminothiolane-HCl (Pierce Chemical Co., Rockford, IL) and 500 nmol NAD<sup>+</sup> in 1 ml 0.1 M phosphate buffer (pH 8.0) containing 1 mM EGTA at 37 °C for 1 h. The derivatized PE was then separated from the reactants using HPLC and activated by the addition of 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB) to a final concentration of 1 mM. Antibodies (40-50 nmol) were incubated with 100-200 nmol 2-iminothiolane-HCl in 0.75 ml 0.1 M phosphate buffer (pH 8.0) containing 1 mM EGTA at 37 °C for 1 h. The antibodies were reacted with the activated PE and the conjugates were purified using HPLC as described. Pirker et al. (1985). A peak containing a one-to-one conjugate of PE with the antibody was recovered and used for all studies described below.

Inhibition of protein synthesis and ID<sub>50</sub>s were determined as described above in Example IV except that the cells were incubated with immunotoxin for 12 hrs. Results from representative protein inhibition assays are shown and the average ID<sub>50</sub> values of all experiments are provided in Table 13. ID<sub>50</sub>s are shown as ng/ml and (nM) in the table.

TABLE 13

ID <sub>50</sub> -Values in ng/ml (nM) for Protein Synthesis Inhibition <sup>a</sup>			
Cells	454C11-PE	260F9-PE	280D11-PE
OVCAR-2	1.6(0.01)	3.4(0.02)	835(4)
OVCAR-3	3.6(0.02)	41.5(0.2)	805(4)
OVCAR-4	0.7(0.005)	4.7(0.02)	54(0.3)
OVCAR-5	10(0.05)	23(0.1)	3450(>15)
A1847	2.5(0.015)	385 <sup>c</sup> (2)	2200(>10)
KB	15 <sup>b</sup> (0.08)	>600(>3)	>250(>1)

<sup>a</sup> If not otherwise mentioned, these values are mean values of at least two experiments.

<sup>b</sup> Results from one experiment.

<sup>c</sup> Non-specific toxicity.

Samples of the hybridomas that produce the monoclonal antibodies from which the immunotoxins according to the invention are derived have been deposited in the American Type Culture Collection or the Collections of *In Vitro* International under the following accession numbers:

ATCC	
Hybridoma	Accession No.
788G6	HB 8692

5

10

15

In Vitro International Collection	
Hybridoma	Accession No.
9C6	IVI 10056
44B2	IVI 10068
44F4	IVI 10058
120H7	IVI 10061
200F9	IVI 10062
204F4	IVI 10071
219F3	IVI 10072
388D4	IVI 10065
421E8	IVI 10064
871E3	IVI 10084
451C3	IVI 10081
650E2	IVI 10083
454A12	IVI 10075

These deposits were made under the Budapest Treaty and will be maintained and made accessible in accordance with the provisions thereof.

#### Claims

1. An immunotoxin which comprises a cytotoxic moiety and an antigen binding portion selected from the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody which binds human ovarian cancer tissue and is selected from those obtainable from IVI 10068, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10064, HB 8692 and IVI 10084  
said immunotoxin having at least one capability selected from:  
a cytotoxicity ID<sub>50</sub> of about 10 nM or less against human ovarian cancer cells; retarding the rate of growth of tumours comprised of human ovarian cancer cells carried by a mammal when said mammal is treated with said immunotoxin; or extending the survival time of a mammal bearing a tumour comprised of human ovarian cancer cells when said mammal is treated with said immunotoxin.
2. An immunotoxin as claimed in Claim 1 wherein the human ovarian cancer cells are at least one selected from the group consisting of OVCAR-2, OVCAR-3, OVCAR-4, OVCAR-5 and A1847.
3. An immunotoxin as claimed in Claim 1 or Claim 2 wherein the toxic moiety is an enzymatically active toxin of bacterial, plant or fungal origin, selected from the group consisting of ricin toxin A chain, *Phytolacca americana* proteins, diphtheria toxin A fragment, non-binding active fragments of diphtheria toxin A fragment and *Pseudomonas aeruginosa* exotoxin A.
4. An immunotoxin as claimed in Claim 3 wherein the ricin toxin A chain is recombinant ricin toxin A chain.
5. An immunotoxin as claimed in any one of Claims 1 to 4 wherein said antigen binding portion of a monoclonal antibody comprises the F(ab')<sub>2</sub> portion thereof.
6. The use of an antigen binding moiety selected from the group consisting of the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody selected from those obtainable from IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 and IVI 10084 in the manufacture of a medicament for use against human ovarian cancer by the provision of an immunotoxin comprising said antigen binding moiety and a cytotoxic moiety.
7. The use of Claim 6 further defined by the specific feature(s) of any one or more of Claims 2 to 5.
8. A formulation for retarding the growth of tumors comprised of human ovarian cancer cells or for killing human ovarian cancer cells comprising an immunotoxin of any one of Claims 1 to 5 formulated for such use.

9. A formulation as claimed in Claim 8 comprising an immunotoxin of any one of Claims 1 to 5 and a diluent, carrier or excipient suitable for parenteral administration.
10. An immunotoxin as claimed in any one of Claims 1 to 5 for use in the treatment of disease.
11. The use of an immunotoxin comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of the Fab, Fab' and F(ab')<sub>2</sub> regions of a monoclonal antibody selected from those obtainable from IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 and IVI 10084 in the manufacture of a medicament for retarding the growth of tumours comprised of human ovarian cancer cells or for killing human ovarian cancer cells.
12. A method of making an immunotoxin as claimed in any one of Claims 1 to 5 comprising conjugating or linking an antigen binding portion and a cytotoxic moiety as defined in Claim 1.

#### Revendications

1. Immunotoxine qui comprend un fragment cytotoxique et une portion se liant à l'antigène, choisie parmi les régions Fab, Fab' et F(ab')<sub>2</sub> d'un anticorps monoclonal qui se lie au tissu de cancer ovarien humain et est choisi parmi ceux obtenus à partir d'IVI 10068, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10064, HB 8692 et IVI 10084  
ladite immunotoxine ayant au moins une propriété choisie parmi :  
une cytotoxicité DL<sub>50</sub> d'environ 10 nM ou moins contre les cellules de cancer ovarien humain ; le ralentissement de la croissance des tumeurs constituées de cellules de cancer ovarien humain portées par un mammifère lorsque ce mammifère est traité avec ladite immunotoxine ; ou l'allongement du temps de survie d'un mammifère portant une tumeur constituée de cellules de cancer ovarien humain lorsque ce mammifère est traité avec ladite immunotoxine.
2. Immunotoxine selon la revendication 1, dans laquelle les cellules de cancer ovarien humain sont au moins une de celles choisies dans le groupe constitué par OVCAR-2, OVCAR-3, OVCAR-4, OVCAR-5 et A1847.
3. Immunotoxine selon la revendication 1 ou la revendication 2, dont le fragment toxique est une toxine enzymatiquement active d'origine bactérienne, végétale ou fongique choisie dans le groupe constitué par la chaîne A de la toxine ricine, les protéines de *Phytolacca americana*, le fragment A de la toxine diphtérique, les fragments actifs non liants du fragment A de la toxine diphtérique et l'exotoxine A de *Pseudomonas aeruginosa*.
4. Immunotoxine selon la revendication 3, dans laquelle la chaîne A de la toxine ricine est une chaîne A de la toxine ricine recombinante.
5. Immunotoxine selon l'une quelconque des revendications 1 à 4, dans laquelle ladite portion se liant à l'antigène d'un anticorps monoclonal comprend sa portion F(ab')<sub>2</sub>.
6. Utilisation d'un fragment se liant à l'antigène, choisi dans le groupe constitué par les régions Fab, Fab' et F(ab')<sub>2</sub> d'un anticorps monoclonal choisi parmi ceux pouvant être obtenus à partir d'IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 et IVI 10084 dans la préparation d'un médicament utile contre le cancer ovarien humain par l'apport d'une immunotoxine comprenant ledit fragment se liant aux antigènes et un fragment cytotoxique.
7. Utilisation de la revendication 6 définie de plus par une ou plusieurs caractéristiques spécifiques d'une ou plusieurs des revendications 2 à 5.
8. Formulation pour ralentir la croissance des tumeurs comprenant des cellules de cancer ovarien humain ou pour tuer des cellules de cancer ovarien humain comprenant une immunotoxine de l'une quelconque des revendications 1 à 5 formulée à cette fin.

9. Formulation selon la revendication 8 comprenant une immunotoxine de l'une quelconque des revendications 1 à 5 et un diluant, support ou excipient appropriés à l'administration parentérale.
10. Immunotoxine selon l'une quelconque des revendications 1 à 5 pour l'emploi dans le traitement d'une  
5 maladie.
11. Utilisation d'une immunotoxine comprenant un fragment cytotoxique et une portion se liant à l'antigène choisie dans le groupe constitué par les régions Fab, Fab' et F(ab')<sub>2</sub> d'un anticorps monoclonal choisi parmi ceux pouvant être obtenus à partir d'IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI  
10 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 et IVI 10084 dans la fabrication d'un médicament pour ralentir la croissance de tumeurs constituées de cellules de cancer ovarien humain ou pour tuer des cellules de cancer ovarien humain.
12. Procédé pour préparer une immunotoxine selon l'une quelconque des revendications 1 à 5 comprenant  
15 la conjugaison ou la liaison d'une portion se liant à l'antigène et d'un fragment cytotoxique, comme défini dans la revendication 1.

#### Patentansprüche

- 20 1. Immunotoxin enthaltend einen cytotoxischen Teil und einen Antigen-bindenden Teil, ausgewählt aus den Fab-, Fab'- und F(ab')<sub>2</sub>-Regionen eines menschlichen Eierstockkrebsgewebe bindenden monoclonalen Antikörpers, der aus IVI 10068, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10064, HB 8692 oder IVI 10084 erhältlich ist, wobei das Immunotoxin mindestens eine der nachfolgenden Fähigkeiten aufweist:  
25 eine Cytotoxizitäts-ID<sub>50</sub> von etwa 10 nM oder weniger gegen menschliche Eierstockkrebszellen; Verzögerung der Wachstumsrate von Tumoren, die aus menschlichen Eierstockkrebszellen bestehen, die von einem Säuger getragen werden, wenn der Säuger mit dem Immunotoxin behandelt wird; oder Verlängerung der Überlebenszeit eines Säugers, der einen aus menschlichen Eierstockkrebszellen bestehenden Tumor trägt, wenn der Säuger mit dem Immunotoxin behandelt wird.  
30
2. Immunotoxin nach Anspruch 1, wobei unter die menschlichen Eierstockkrebszellen mindestens eine aus der Gruppe OVCAR-2, OVCAR-3, OVCAR-4, OVCAR-5 und A1847 fällt.
3. Immunotoxin nach Anspruch 1 oder 2, wobei der toxische Teil ein enzymatisch aktives Toxin bakteriellen, pflanzlichen oder Pilz-Ursprungs ist, ausgewählt aus der Gruppe bestehend aus der  
35 Ricintoxin A-Kette, Phytolacca americana-Proteinen, dem Diphtherietoxin A-Fragment, nicht-bindenden aktiven Fragmenten des Diphtherietoxin A-Fragments und Pseudomonas aeruginosa-Exotoxin A.
4. Immunotoxin nach Anspruch 3, wobei die Ricintoxin A-Kette eine rekombinante Ricintoxin A-Kette ist.  
40
5. Immunotoxin nach einem der Ansprüche 1 bis 4, wobei der Antigen-bindende Teil eines monoclonalen Antikörpers den F(ab')<sub>2</sub>-Teil davon enthält.
6. Verwendung eines Antigen-bindenden Teils ausgewählt aus der Gruppe bestehend aus den Fab-, Fab'- und F(ab')<sub>2</sub>-Regionen eines monoclonalen Antikörpers, der aus IVI 10056, IVI 10068, IVI 10058, IVI  
45 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 oder IVI 10084 erhältlich ist, in der Herstellung eines Arzneimittels zur Verwendung gegen menschlichen Eierstockkrebs durch die Bereitstellung eines Immunotoxins, das den Antigen-bindenden Teil und einen cytotoxischen Teil enthält.  
50
7. Verwendung nach Anspruch 6, weiterhin gekennzeichnet durch das (die) bestimmte(n) Merkmal(e) nach einem oder mehreren der Ansprüche 2 bis 5.
8. Formulierung zur Verzögerung des Wachstums von Tumoren, die aus menschlichen Eierstockkrebszellen  
55 bestehen, oder zum Abtöten von menschlichen Eierstockkrebszellen, enthaltend ein Immunotoxin nach einem der Ansprüche 1 bis 5, das für eine solche Verwendung formuliert ist.
9. Formulierung nach Anspruch 8, enthaltend ein Immunotoxin nach einem der Ansprüche 1 bis 5 und ein

Verdünnungsmittel, einen Träger oder einen Exzipienten, das (der) für die parenterale Verabreichung geeignet ist.

10. Immunotoxin nach einem der Ansprüche 1 bis 5 zur Verwendung bei der Behandlung einer Krankheit.

5

11. Verwendung eines Immunotoxins enthaltend einen cytotoxischen Teil und einen Antigen-bindenden Teil ausgewählt aus der Gruppe bestehend aus den Fab-, Fab'- und F(ab')<sub>2</sub>-Regionen eines monoclonalen Antikörpers, der aus IVI 10056, IVI 10068, IVI 10058, IVI 10061, IVI 10062, IVI 10071, IVI 10072, IVI 10065, IVI 10064, IVI 10075, IVI 10081, IVI 10083, HB 8692 oder IVI 10084 erhältlich ist, in der Herstellung eines Arzneimittels zur Verzögerung des Wachstums eines Tumors, der aus menschlichen Eierstockkrebszellen besteht, oder zum Abtöten von menschlichen Eierstockkrebszellen.

10

12. Verfahren zur Herstellung eines Immunotoxins nach einem der Ansprüche 1 bis 5, wobei man einen Antigen-bindenden Teil und einen cytotoxischen Teil nach Anspruch 1 konjugiert oder verbindet.

15

20

25

30

35

40

45

50

55